No registrations found.
ID
Source
Brief title
Intervention
Outcome measures
Primary outcome
3-month change in positive and negative symptoms on the total PANSS score.
Secondary outcome
3-month change in the PANSS subscales, cognitive symptoms, immunological parameters (g-interferon, IL-4, IL-6 and IL-12).
Background summary
N/A
Study objective
Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia.
Intervention
Acetylsalicylacid 1000mg vs Placebo for 3 months (All daily pantoprazol 40 mg).
P.O. Box 30.001
H. Burger
Hanzeplein 1
Groningen 9700 RB
The Netherlands
H.Burger@rug.nl
P.O. Box 30.001
H. Burger
Hanzeplein 1
Groningen 9700 RB
The Netherlands
H.Burger@rug.nl
Inclusion criteria
1. Schizophrenia
2. Schizo-affective disorder
3. Schizofreniform disorder according to DSM-IV (for max 10 years)
4. Age 18 - 55 years
5. Stabile, min. 60 on PANSS, min 2x a score of min 4 on PANSS.
Exclusion criteria
1. No contraindication for acetylsalicylic acid
2. No hypersensitivity to acetylsalicylic acid or pantoprazole
3. No significant somatic illness
4. No chronic use of a nonsteroidal anti-inflammatory drug (NSAID)
5. No use of corticosteroids
5. Not pregnant
6. No drugs dependency
7. Informed consent obtained.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL5 |
| NTR-old | NTR29 |
| Other | : N/A |
| ISRCTN | ISRCTN27745631 |